Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: edwards r. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. Ann Oncol. 2017. PMID: 28453702 Free PMC article. Clinical Trial.
Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP. Sit AS, et al. Among authors: edwards rp. Gynecol Oncol. 2000 Nov;79(2):196-200. doi: 10.1006/gyno.2000.5956. Gynecol Oncol. 2000. PMID: 11063643
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL. Monk BJ, et al. Among authors: edwards r. Gynecol Oncol. 2011 Mar;120(3):459-63. doi: 10.1016/j.ygyno.2010.11.012. Epub 2010 Dec 7. Gynecol Oncol. 2011. PMID: 21144560 Clinical Trial.
In vitro chemoresponse in metachronous pairs of ovarian cancers.
Dalton HJ, Fiorica JV, Edwards RP, Benjamin I, Rocconi RP, Recio FO, Lovecchio JL, Burrell MO, Shahin MS, Grendys EC, Wang D, Wang T, Monk BJ. Dalton HJ, et al. Anticancer Res. 2014 Dec;34(12):7191-6. Anticancer Res. 2014. PMID: 25503148
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS. Creasman WT, et al. Among authors: edwards rp. Gynecol Oncol. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017. Epub 2017 Apr 6. Gynecol Oncol. 2017. PMID: 28392124 Free PMC article.
5,250 results